ClinicalTrials.gg
CompletedNCT00294918Updated Mar 26, 2014

An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome

A Phase 2/3 interventional study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) and Human Immunodeficiency Virus Infections, sponsored by EMD Serono. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-26.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multi-center, randomized, parallel-group, maintenance trial of Serostim® in subjects who have completed a prior Serostim® Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) trial (Study 22388). The subjects, who encountered toxicity during the antecedent protocol, will be assigned to a 1 milligram (mg) dose. All other subjects will be randomized in 1:1 ratio, to receive up to 2 mg or 4 mg of Serostim®, beginning from Day 1 of Week 1. Doses will be adjusted downward in subjects weighing less than 55 kilogram (kg). Serostim® therapy will be continued at the assigned doses through Week 12 (Period 1). Subjects, who will encounter toxicity during Period 1, will be assigned to the 1 mg group for Period 2. All other subjects will be randomized in a 1:1 ratio to receive up to 2 mg or 1 mg of Serostim® on a weight adjusted basis. Period 2 therapy will begin on Day 1 of Week 13, continuing through Week 36. Study visits are required at Screening (that is, Final Visit of the antecedent trial), Day 1 of Week 1 (Baseline), and at Weeks 2, 6, 12, 14, 24, 30 and 36.

02

Conditions studied

  • Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
  • Human Immunodeficiency Virus Infections

Keywords

  • Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
  • Human Immunodeficiency Virus Infections
  • Serostim®
  • recombinant human growth hormone (r-hGH)
03

In context

Lead sponsor

EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.

First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Complete all treatments prescribed by the antecedent protocol (Study 22388)
  • Be able and willing to comply with the protocol for the duration of the study, including concomitant therapy restrictions
  • Have given written
  • If female, be , surgically sterile, or using adequate

Exclusion criteria

Exclusion Criteria:

  • Experienced a protocol defined toxicity or any other adverse event, which caused premature withdrawal from the antecedent study (Study 22388)
  • Withdrew from the antecedent study or was discontinued prematurely for any other reason
  • Based on the Final Visit evaluations from the antecedent trial, would be required to withdraw from the antecedent protocol, if (theoretically) the antecedent trial continued beyond the Final Visit
  • Based on the Final Visit evaluations from the antecedent trial, would be required to temporarily stop or reduce the dose of study drug, if (theoretically) the antecedent trial continued beyond the Final Visit. This does not apply to subjects whose study drug was temporarily stopped or whose study drug dose was reduced prior to the Final Visit (Screening), provided they continued in the antecedent protocol and are stable at the time of the Final Visit (Screening)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Serostim® (1 mg)

    Drug: Serostim®

  • Experimental
    Serostim® (2 mg)

    Drug: Serostim®

  • Experimental
    Serostim® (4 mg)

    Drug: Serostim®

Interventions

  • DrugHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.

    Also known as: recombinant human growth hormone (r-hGH)

06

What researchers measure

Primary outcomes

  1. Percent change from Week 12 in trunk fat quantified by Dual-energy X-ray absorptiometry (DXA) at Week 36

    Time frame: Week 12 and Week 36

Secondary outcomes

  1. Change from Week 12 in ratio of trunk fat to limb fat quantified by DXA at Week 36

    Time frame: Week 12 and Week 36

  2. Change from Week 12 in weight measured on a calibrated scale at Week 36

    Time frame: Week 12 and Week 36

  3. Change from Week 12 in total body fat quantified by DXA at Week 36

    Time frame: Week 12 and Week 36

  4. Change from Week 12 in lean body mass quantified by DXA at Week 36

    Time frame: Week 12 and Week 36

  5. Change from Week 12 in maximal chest, waist, and hip circumference at Week 36

    Time frame: Week 12 and Week 36

  6. Change from Week 12 in waist/hip ratio at Week 36

    Time frame: Week 12 and Week 36

  7. Change from Week 12 in Dorsocervical Fat Pad at Week 36

    Time frame: Week 12 and Week 36

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Low-dose Maintenance Therapy with Recombinant Human Growth Hormone Sustains Effects of Previous r-hGH Treatment in HIV+ Patients with Excess Center Fat: Treatment Results at 60 Weeks D P Kotler, C Grunfeld, N Muurahainen, C Wanke, M Thompson, D Bock, J Gertner, and Serostim in the Treatment of Adipose Redistribution Syndrome (STARS) Trial Investigator Group. Abstract. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2004, Moscone West, San Francisco CA, USA.

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2001, a primary completion of Feb 2003 and a completion of Feb 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2006
First posted
Feb 22, 2006
Start
Sep 2001
Primary completionActual
Feb 2003
CompletionActual
Feb 2003
Last update
Mar 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00294918
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Feb 22, 2006
Start date
Sep 2001
Primary completion
Feb 2003
Completion
Feb 2003
Last update
Mar 26, 2014

Study contacts

Norma Muurahainen, M.D. PhD
study director · EMD Serono
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion